Skip to main content
. 2015 Jun 30;17(11):1504–1513. doi: 10.1093/neuonc/nov104

Table 2.

Response rates (n (%)) by treatment group

Response Bevacizumab + Carboplatin (N = 58) Bevacizumab (N = 62) P
Objective response (complete or partial response) 8 (14%) 4 (6%) .18
Best response .23
 Partial response 8 (14%) 4 (6%)
 Stable disease 36 (62%) 36 (58%)
 Progressive disease 14 (24%) 22 (35%)